Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings
Eluminex announced today it acquired rights for a novel oral therapy to treat LCA or RP caused mutations of the RPE65 or LRAT gene.
Search
- Jul 5, 2021
The Lrat−/− Rat: CRISPR/Cas9 Construction and Phenotyping of a New Animal Model for RP
Researchers developed and phenotyped a pigmented knockout rat model for lecithin retinol acyltransferase (LRAT) using CRISPR/Cas9.
- Jun 29, 2012
Early Onset Retinal Dystrophy Due to Mutations in LRAT:
Phenotypic similarities to the retinal dysfunction assoc. with RPE65 mutations, suggest that LRAT deficiency may respond to novel therapies.